Welcome to glucagon.com: a webpage devoted to the study of the glucagon-like peptides,
and homepage of the Drucker Lab at Toronto's Lunenfeld-Tanenbaum Research Institute (LTRI) at
Mount Sinai Hospital, directly adjacent to the University of Toronto campus.
Our laboratory carries out studies of the physiology of gut peptides, encompassing the
mechanisms controlling their bioactivity, with a focus on glucagon and the glucagon-like
peptides and their receptors. The laboratory is comprised of research technicians, research associates,
and research fellows appointed to the
Department of Medicine at the University of Toronto.
Explore our recent research, publications
and research reagents here.
RECENT HIGHLIGHTS
Turning Lab Breakthroughs into Medicine: The 1 in 10,000 Challenge in Science, CIHR Feb 2025Q&A with Daniel Drucker: The history and future of GLP-1 research, Cell Sept 2024
The benefits of GLP-1 drugs beyond obesity, Science Jul 2024
Study finds new roles for gut hormone GLP-1 in the brain, U of T News Jan 2024
Follow Dr. Drucker on X: @DanielJDrucker
Featured post:
Some new information about the anti-inflammatory actions of GIP from @RolaHammoud1 Gain and loss of GIPR signaling modifies gut inflammation in mice with 5FU-induced enteritis, with data on Tirzepatide & Semaglutide @JCI_insight @BBDC_UofT @SinaiHealth @CIHR_IRSC pic.twitter.com/k8Dx11i4Dm
— Daniel J Drucker (@DanielJDrucker) December 26, 2024